Efficacy and safety of first-line CDK4/6 inhibitors plus AI therapy for patients with HR +/HER2- advanced breast cancer: a network meta-analysis. Kang Y, Han B, Kong Y, Liu S, et al. BMC Cancer 2025;25:843.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kang Y, Han B, Kong Y, Liu S, et al. Efficacy and safety of first-line CDK4/6 inhibitors plus AI therapy for patients with HR +/HER2- advanced breast cancer: a network meta-analysis. BMC Cancer 2025;25:843.
PMID: 40340824